Skip to content
AnalystLens

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 6, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed February 6, 2025
Period End
February 6, 2025
Securities
BMYCELG-RIBMYMP
In the record · 2016–202610-K1110-Q328-K169

BMY filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 169 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Mar ’22Mar ’22
  3. Leadership change8-K · Mar ’24Mar ’24

01—Abstract

Summary

Summary of the 8-K filed February 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Bristol Myers Squibb reported Q4 2024 revenues of $12.3 billiona, up 8% (9% ex-FX), with the Growth Portfolio reaching $6.4 billion (+21%, or +23% ex-FX) and Legacy Portfolio revenues declining 4% to $6.0 billion.

GAAP EPS was $0.04b versus $0.87 a year earlier, driven by intangible asset impairments and IPR&D charges, while non-GAAP EPS was $1.67 versus $1.70. For full year 2024, revenues were $48.3 billion (+7%, +9% ex-FX), but GAAP results showed a loss of $(4.41) per share, largely due to a one-time ~$12.1 billion acquired IPR&D charge tied to the Karuna acquisition and an ~$0.8 billion SystImmune collaboration charge. Non-GAAP EPS was $1.15, down from $7.51, reflecting roughly $(6.39) per share of net IPR&D impact.

Management emphasized the ongoing shift toward the Growth Portfolio, highlighting strong demand for Reblozyl, Breyanzi, Camzyos and Opdualag, the U.S. launch of Cobenfy in schizophrenia, and the U.S. approval of Opdivo Qvantig. The company expanded its strategic productivity initiative to deliver about $2 billionc in additional annualized cost savings by the end of 2027, with roughly $1 billion expected in 2025. Net debt rose to $38.5 billion from $27.1 billion at year-end 2023, and management plans to pay down about $10 billion of debt by the end of the first half of 2026.

For 2025, guidance calls for total revenues of about $45.5 billiond, reflecting an expected 18-20% decline in the Legacy Portfolio from generic erosion (notably Revlimid, Pomalyst, Sprycel and Abraxane) and roughly $500 million of FX headwind. Non-GAAP EPS is guided to $6.55-$6.85, with gross margin near 72% and operating expenses near $16 billion. Investors will focus on whether Growth Portfolio momentum and cost savings can offset the Legacy cliff, and on the sustainability of the Cobenfy launch and the pipeline readouts planned for 2025-2027.

02—Key points

Key Highlights

  1. Q4 2024 revenues rose 8% to $12.3 billion (9% ex-FX), with the Growth Portfolio up 21% to $6.4 billion, while GAAP EPS fell to $0.04 from $0.87 due to impairments and IPR&D charges.
  2. Full-year 2024 revenues reached $48.3 billion (+7%, +9% ex-FX), but GAAP EPS was $(4.41) because of a ~$12.1 billion one-time Karuna-related IPR&D charge; non-GAAP EPS was $1.15 versus $7.51 in 2023.
  3. Growth Portfolio full-year revenues grew 17% to $22.6 billion, led by Reblozyl, Breyanzi, Camzyos and Opdualag, while the Legacy Portfolio was flat at $25.7 billion.
  4. Expanded strategic productivity initiative targets ~$2 billion in additional annualized cost savings by end-2027, with ~$1 billion expected in 2025.
  5. 2025 guidance: revenues of ~$45.5 billion (Legacy Portfolio expected to decline 18-20%) and non-GAAP EPS of $6.55-$6.85.
  6. Net debt increased to $38.5 billion from $27.1 billion at year-end 2023, with a planned ~$10 billion debt paydown by the end of 1H 2026; the dividend was reaffirmed, subject to Board approval.
  7. Pipeline catalysts include Cobenfy adjunctive schizophrenia and Alzheimer's psychosis data, Camzyos nHCM, and Milvexian readouts through 2027.

03—Questions

Frequently Asked Questions

  1. Why was BMS's GAAP EPS so much weaker than its non-GAAP EPS in 2024?

    The gap was driven mainly by a one-time acquired IPR&D charge of about $13.4 billion for the year, including roughly $12.1 billion from the Karuna acquisition and about $0.8 billion from the SystImmune collaboration. GAAP results also included large intangible asset impairments and amortization of acquired intangibles, which non-GAAP results exclude.

  2. How much will the Legacy Portfolio decline in 2025, and why?

    Management guides to an approximate 18-20% decline in Legacy Portfolio revenues in 2025. The drop reflects generic competition for Revlimid, Pomalyst, Sprycel and Abraxane, and Revlimid alone is expected to generate roughly $2-2.5 billion in worldwide sales.

  3. What is the Growth Portfolio, and how is it performing?

    The Growth Portfolio includes newer and key brands such as Opdivo, Reblozyl, Breyanzi, Camzyos, Cobenfy and Opdualag. It grew 17% to $22.6 billion in 2024 and 21% in Q4, and management expects it to offset much of the Legacy decline going forward.

  4. How is BMS managing its balance sheet after the Karuna acquisition?

    Net debt rose to $38.5 billion at year-end 2024, and total debt was about $49.6 billion. Management plans to repay roughly $10 billion of debt by the end of 1H 2026 while maintaining its investment-grade rating and dividend, and it still has about $5 billion remaining under its share repurchase authorization.

  5. What are the key drivers of the new cost savings program?

    The expanded strategic productivity initiative targets about $2 billion of additional annualized savings by the end of 2027, roughly half from organizational design changes that streamline the workforce and half from operational efficiency improvements. About $1 billion is expected to be realized in 2025, and management indicates the savings will flow to the bottom line.

04—Continue

← View all 8-K filings